$1.12
-0.97 (-46.41%)
Open$2.23
Previous Close$2.09
Day High$2.40
Day Low$1.11
52W High$5.74
52W Low$2.03
Volume—
Avg Volume37.4K
Market Cap23.38M
P/E Ratio—
EPS$-1.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,219.6% upside
Current
$1.12
$1.12
Target
$25.98
$25.98
$20.93
$25.98 avg
$39.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.75M | 4.21M | 3.91M |
| Net Income | 909.1K | 778.9K | 578.2K |
| Profit Margin | 19.1% | 18.5% | 14.8% |
| EBITDA | 1.38M | 1.12M | 1.11M |
| Free Cash Flow | 932.9K | 1.05M | 869.6K |
| Rev Growth | +21.8% | +17.5% | +9.1% |
| Debt/Equity | 0.24 | 0.30 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |